摘要
目的 探讨不同剂量瑞舒伐他汀对急性心肌梗死(AMI)患者血清心肌营养素1(CT-1)水平及心功能的影响.方法 将112例AMI患者按照用药剂量分为2组,瑞舒伐他汀常规剂量治疗组(常规剂量组,60例)患者在常规应用阿司匹林、氯吡格雷、硝酸盐类、β受体阻滞剂等药物治疗基础上加服瑞舒伐他汀10 mg/d;瑞舒伐他汀强化剂量治疗组(强化剂量组,52例)患者在常规药物治疗基础上加服瑞舒伐他汀20 mg/d.另完全随机选取40例体检正常者作为对照组.对照组于AMI患者用药前,常规剂量组、强化剂量组分别于用药前及用药后4周空腹静脉采血检测CT-1水平并检查超声心动图指标,包括左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)和左心室射血分数(LVEF).结果 用药前常规剂量组、强化剂量组CT-1水平、LVEDD及LVESD[(333 ±53) ng/L、(339 ±51)ng/L,(59.5±6.4)mm、(58.2±7.6) mm,(40.7 ±7.4) mm、(40.4 ±6.2) mm]明显高于对照组[(42.6±11.2) ng/L,(38.2±1.8)mm,(30.2±1.2)mm],LVEF[(41.1±6.8)%、(41.4±7.2)%]明显低于对照组[(58.2±0.9)%],用药后4周,CT-1水平、LVEDD及LVESD[(152 ±28) ng/L、(108± 19)ng/L,(52.1 ±6.1)mm、(46.4±4.9)mm,(34.5 ±4.6)mm、(30.9±4.2)mm]明显降低,LVEF明显升高[(47.5±6.1)%、(52.8±6.2)%],差异均有统计学意义(P<0.05).与常规剂量组比较,强化剂量组上述指标改善更为明显(P<0.05).结论 瑞舒伐他汀可有效降低患者CT-1水平,抑制心室重塑,改善患者心功能.
Objective To investigate the effects of different doses of rosuvastatin on serum concentration of cardiotrophin-1 (CT-1) and cardiac function in acute myocardial infarction (AMI) patients.Methods One hundred and twelve AMI patients were randomly divided into two groups.The conventional dose rosuvastatin group (60 cases) took 10 mg/d rosuvastatin in addition to routine therapy (such as aspirin clopidogrel nitrate and β-blocker) ; the strengthening dose group(52 cases) took 20mg/d rosuvastatin in addition to routine therapy.40 cases of normal physical examination were randomly selected as the control group.The levels of CT-1,left ventricular enddiastolic diameter(LVEDD),left ventricular end-systolic dimension(LVESD) and ejection fraction(EF) were all measured in three groups before and after 4 weeks treatment.Results Before treatment,the levels of CT-1,LVEDD and LVESD in the conventional dose group and the strengthening dose group [(333 ± 53) ng/L,(339 ± 51) ng/L ; (59.5 ± 6.4) mm,(58.2 ± 7.6) mm ; (40.7 ± 7.4) mm,(40.4 ± 6.2) mm] were significantly higher than those in the control group [(42.6 ± 11.2) ng/L,(38.2 ± 1.8) mm,(30.2 ± 1.2) mm] (P 〈 0.05) ; the levels of EF[(41.1 ± 6.8)%,(41.4 ± 7.2)%] were significantly lower than those in the control group[(58.2 ± 0.9) %] (P 〈 0.05).After 4 weeks later,the levels of CT-1,LVEDD and LVESD were all decreased significantly [(152±28) ng/L,(108± 19)ng/L;(52.1 ±6.1) mm,(46.4 ±4.9)mm;(34.5 ±4.6)mm,(30.9 ±4.2)mm] ; the levels of EF were increased[(47.5 ± 6.1) %,(52.8 ± 6.2) %].Conclusion Rosuvastatin can inhibit ventricular remodeling and improve cardiac function and long term prognosis.
出处
《中国医药》
2014年第12期1735-1737,共3页
China Medicine
基金
河北省科学技术研究与发展计划(112761123)
河北省科学技术成果(20140270)